What is Zoobiotic?
Zoobiotic operates at the intersection of biological science and clinical wound care, specializing in Larval Therapy. The company provides natural, highly effective debridement solutions designed to address non-healing or infected wounds that often prove resistant to conventional medical interventions. By utilizing live larvae within a proprietary, sealed delivery system, Zoobiotic offers a precise and gentle method for tissue cleaning, which significantly improves patient quality of life and reduces the burden on traditional healthcare facilities.
As a global pioneer in this niche, the company maintains a dual focus: delivering high-efficacy medical products and providing comprehensive support to healthcare practitioners. Their market position is defined by a commitment to evidence-based healing, bridging the gap between ancient biological practices and modern clinical standards to solve persistent challenges in chronic wound management.
How much funding has Zoobiotic raised?
Zoobiotic has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2014): $5.9M with participation from Finance Wales and Oxford Capital Partners
Key Investors in Zoobiotic
Finance Wales
The Development Bank of Wales provides sustainable business finance solutions, including equity and loans, to support economic growth and technology ventures within the region.
Oxford Capital Partners
An established investment manager focused on providing growth capital to smaller companies across diverse industries to help entrepreneurs scale their businesses.
What's next for Zoobiotic?
With the recent strategic investment, Zoobiotic is well-positioned to accelerate its market penetration and refine its product delivery infrastructure. The company is expected to focus on scaling its manufacturing capabilities to meet the rising demand for non-invasive wound care solutions. Furthermore, the strategic backing provides the necessary resources to deepen clinical research and expand its footprint in international markets, where the demand for cost-effective, high-performance wound care continues to grow.
Future growth will likely center on enhancing practitioner education and strengthening the supply chain to ensure consistent, high-quality patient outcomes. By maintaining its focus on innovation and clinical excellence, Zoobiotic is poised to remain a leader in the evolving landscape of biological wound management, potentially setting new standards for patient-centric care in the coming years.
